Postoperative Nausea and Vomiting Implications in Neostigmine versus Sugammadex by Johnson, Corey Lee et al.
Purpose
The purpose of this DNP project is to determine if the 
neuromuscular blockade (NMB) reversal agents neostigmine and 
sugammadex affect the incidence of postoperative nausea and 
vomiting (PONV).
Specific Aims
● Compare PONV rates with neostigmine versus sugammadex
● Determine if pharmacologic decision-making can be justified for 
PONV prophylaxis
● Identify gaps in current literature regarding paralytic reversals’ 
effects on PONV
● Consider confounding factors that could also contribute to 
PONV regardless of drug
○ i.e. Female gender, non-smoking status, postoperative opioid 
consumption
Presenters: Corey Johnson, BSN, RN, SRNA, Colton James, BSN, RN, SRNA, Sarah Traughber, BSN, RN, SRNA, Charles Walker, BSN, RN, SRNA
Faculty Advisor: Dr. Dwayne Accardo, DNP, APRN, CRNA
College of Nursing - The University of Tennessee Health Science Center - Memphis, TN
Postoperative Nausea and Vomiting Implications in Neostigmine versus Sugammadex 
Background
• PONV is one of the most common postoperative complaints 
by patients
• Current prevention of PONV revolves around pre-
medication with antiemetics and minimizing exposure to 
triggers
• PONV can initiate a trend of poor outcomes when it 
persists, such as delaying patient discharge and increasing 
costs
• Pharmacologic agents commonly used in anesthesia can 
potentiate PONV
• Neuromuscular blockade (NMB) reversal agents, 
sugammadex and neostigmine, can implicate PONV
o High-dose neostigmine, an acetylcholinesterase 
inhibitor, has been reported to increase PONV by 
stimulating muscarinic receptors and increasing 
acetylcholine (AcH), a known PONV trigger, at the 
chemoreceptor trigger zone (CTZ)
o Sugammadex has considerable benefits by reducing 
adverse drug effects in comparison to neostigmine 
through encapsulating the paralytic agent rather than 
increasing AcH
• Despite an increased cost with sugammadex, it has 
potential to be a rationale for standardized use if PONV can 
be linked to neostigmine
Methods
Eligibility Criteria
○ General anesthesia cases with NMBD use
○ Full-text, English, peer-reviewed articles published between 2014-2020
Information Sources & Search
○ Systematic search conducted between August 2019-November 2020
○ PubMed, CINAHL, MEDLINE (EBSCO), Google Scholar
○ Search Terms: “Sugammadex Neostigmine PONV,” “Neuromuscular 
blockers and PONV,” “Paralytic reversal agents and PONV”
○ Publication date limited to 2014-2020
Selection of Sources of Evidence
○ Meta-analyses, systematic reviews, randomized controlled trials, case 
control studies, or evidence based practice projects
○ Explicit mention of PONV in both groups
○ Abstracts excluded
○ >18 years of age
Data & Synthesis of Results
○ Charted via an electronic table
○ Variables: incidence of PONV in a sugammadex group; incidence of 
PONV in a neostigmine group; incidence of postoperative analgesic 
consumption in a sugammadex group; incidence of postoperative 
analgesic consumption in a neostigmine group
○ Followed PRISMA statement extension for scoping reviews
Results
● 7 out of 8 studies showed an increased incidence of PONV in patients 
reversed with neostigmine over sugammadex reversal
● 2 of the 7 studies showed a statistically significant difference in PONV 
outcomes with neostigmine versus sugammadex
○ Both studies found higher incidence of PONV in the neostigmine 
population compared to the sugammadex population
○
● 5 of the 7 studies that showed a difference in PONV outcomes between the 
two reversal agents did not yield statistically significant results
● 6 of the 8 total studies reviewed did not show a statistically significant 
difference in PONV outcomes in neostigmine versus sugammadex reversal
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Implications for Practice
• Sugammadex provides more effective reversal and has more 
favorable pharmacokinetics
• Sugammadex has less side effects than neostigmine and 
does not require the coadministration of an anticholinergic
• There is not sufficient data suggesting a statistically 
significant reduction in PONV when using sugammadex in 
comparison to neostigmine
● PONV alone is not a sufficient reason for the justification of 
using sugammadex versus neostigmine
o Several hospital pharmacies require a rationale for using 
sugammadex in order to reduce costs 
